CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.
Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074
E-mail : concorddrugsltd@gmail.com Ph.No : +91 9052779505 Website : www.concorddrugs.in

Date: 13.11.2025

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal St, Fort, Mumbai,
Maharashtra 400001

Scrip Code: 538965

Sub: Outcome of Board Meeting held on 13th November, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Further to our intimation dated 04th November, 2025, the Board of Directors, at its meeting held today, has approved the Un-audited (Standalone and Consolidated) Financial Results for the quarter and half year ended 30th September 2025 together with the Limited Review Reports as reviewed & recommended by the Audit Committee.

Further, the Financial results are also available on the website of the Company at (https://concorddrugs.in/investor-relations) and on the website of BSE Ltd viz. www.bseindia.com.

The financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting commenced at 05:00 PM and concluded at 06:45 PM.

This is for the information and record.

Thanking you
Yours Sincerely,

For **Concord Drugs Limited**

Seelam Nagi Reddy
Digitally signed by Seelam Nagi Reddy
Date: 2025.11.13 18:59:43 +05'30'

NAGI REDDY SEELAM
Chairman & Managing Director
(DIN: 01764665)

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

Statement of assets and Liabilities un audited (standalone and Consolidated) for the six months ended 30th September 2025

Rs in lakhs

Particulars	Standalone		Consolidated	
	As on 30th September 2025	As At March 31, 2025	As on 30th September 2025	As At March 31, 2025
ASSETS				
Non-current assets				
(a) Property, plant and equipment	1,083.90	1,153.51	1,087.12	1,157.21
(b) Capital Work-in Progress	205.11	199.65	205.11	199.65
(c) Investment property	63.95	63.95	63.95	63.95
(d) Goodwill	-	-		-
Financial assets	-			
(a) Investments	161.50	**161.50**	79.54	80.01
(b) Loans & Advances	7.89	7.89	7.89	7.89
Other Non current assets	821.33	929.26	821.33	929.26
Total Non - Current Assets	**2,343.67**	**2,515.76**	**2,264.94**	**2,437.97**
Current Assets				
Inventories	1,960.72	1,912.62	2,567.57	2,526.87
Financial assets	-			-
(a) Investments	-			-
(b) Trade receivables	1,631.27	1,267.33	1,724.08	1,360.48
(c) Cash and cash equivalents	16.38	11.54	16.90	12.09
(d) Bank balances other than (c) above	19.61	10.45	19.61	10.45
(e) Other Current Financial Assets	12.10	12.10	12.10	12.10
Other current assets	234.01	128.35	256.10	154.21
Total Current assets	**3,874.09**	**3,342.40**	**4,596.36**	**4,076.21**
Total Assets	**6,217.77**	**5,858.16**	**6,861.30**	**6,514.18**
EQUITY AND LIABILITIES				
Equity				
Equity share capital	1,000.00	1,000.00	1,000.00	1,000.00
Other equity	2,441.89	2,411.36	2,441.89	2,411.36
Total Equity	**3,441.89**	**3,411.36**	**3,441.89**	**3,411.36**
Non-current liabilities				
Financial Liabilities				
(a) Borrowings	79.42	130.80	98.70	132.44
(b) Trade payables	17.22	17.93	17.22	17.93
Deferred tax liabilities, net	62.34	63.72	61.34	62.56
Provisions	271.88	271.88	271.88	271.88
Government Grants	-	-		
Total Non-current liabilities	**430.87**	**484.33**	**449.15**	**484.80**
Current liabilities				
Financial liabilities				
(a) Borrowings	1,410.43	1,355.18	1,610.39	1,586.82
(b) Trade payables	644.07	340.66	1,067.55	762.24
(c) Other Current financial liabilities	205.12	205.12	205.12	205.12
Current tax liabilities, net	31.94	18.99	31.94	20.58
Other current liabilities	53.46	42.52	55.26	43.25
Total Current liabilities	**2,345.01**	**1,962.48**	**2,970.26**	**2,618.02**
Total liabilities	**2,775.88**	**2,446.80**	**3,419.41**	**3,102.82**
Total Equity and liabilities	**6,217.77**	**5,858.16**	**6,861.30**	**6,514.18**

Concord Drugs Limited ★ Hyderabad ★

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Un -Audited Statement Of Consolidated Profit and Loss for the Six months ended 30th September '25 Amount in Lakhs

		Standalone		Consolidated	
	Particulars	**As on 30th September 2025**	**As at March 31, 2025**	**As on 30th September ,2025**	**As at March 31, 2025**
I	**Revenue from Operations**				
	a. Net sales from Operations	2,345.63	3,693.21	2,388.25	4,524.46
II	**Other Income**	0.24	1.44	0.24	1.44
III	**Total Revenue (I+II)**	**2,345.87**	**3,694.65**	**2,388.49**	**4,525.91**
IV	**Expenses**				
	a.Cost of Material Consumed	1,835.81	2,822.46	1,857.57	3,581.09
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	56.13	-58.05	56.13	-58.05
	c. Employees Benefit Expenses	195.11	439.13	198.06	463.45
	d. Finance Costs	81.85	171.84	97.82	202.67
	e. Depreciation and Amortisation expense	70.24	141.80	70.72	143.08
	f. Other expenses	64.61	113.34	65.24	124.54
	Total Expenses	**2,303.75**	**3,630.52**	**2,345.53**	**4,456.77**
	Profit/ (Loss) before Exceptional item and tax (III-IV)	**42.11**	**64.13**	**42.96**	**69.14**
V	**Exceptional Items**	-	-	-	
VI	**Profit/ (Loss) before tax (V+VI)**	**42.11**	**64.13**	**42.96**	**69.14**
VII	**Tax Expense:**	**11.58**	**34.56**	**11.96**	**35.52**
VIII	a. Current tax	12.95	18.99	13.17	20.29
	b. Deferred tax charge/credit	-1.37	15.57	-1.22	15.23
IX	**Profit/ (Loss) for the period (VII-VIII)**	**30.53**	**29.57**	**31.00**	**33.62**
X	**Other Comprehensive Income**	-	-	-	-
	Items that will not be reclassified to profit or loss	-	-	-	
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	**30.53**	**29.57**	**31.00**	**33.62**
XI	**Paid-up equity share capital**	**1,000.00**	**1,000.00**	**1,000.00**	1,000.00
	(Face value of the share- Rs. 10 each)				
XII	**Earnings per share (of Rs. 10 each)**				
XIII	a. Basic (in Rs)	0.31	0.30	0.31	0.34
	b. Diluted (in Rs)	0.31	0.30	0.31	0.34

Concord Drugs Limited ★ Hyderabad ★

Concord Drugs Limited
Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

STATEMENT OF UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30th September 2025

[Rs. in Lakhs]

	Particulars	Quarterly ended			Half Year ended		
		30-Sep-25 (Un Audited)	30-Jun-25 (Un Audited)	30-Sep-24 (Un Audited)	30-Sep-25 (Un Audited)	30-Sep-24 (Un Audited)	31-Mar-25 (Audited)
I	**Revenue from Operations**						
	a. Net sales from Operations	1,027.61	1,360.64	1,236.07	2,388.25	2,405.35	4,524.46
	b. Other Operating Income	0.24	-	0.96	0.24	0.96	1.44
II	**Other Income**						
III	**Total Revenue (I+II)**	**1,027.85**	**1,360.64**	**1,237.02**	**2,388.49**	**2,406.31**	**4,525.91**
IV	**Expenses**						
	a.Cost of Material Consumed	776.35	1,081.22	1,176.65	1,857.57	2,043.64	3,581.09
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-4.51	60.64	-161.22	56.13	-126.06	-58.05
	c. Employees Benefit Expenses	109.46	88.60	93.39	198.06	239.20	463.45
	d. Finance Costs	48.81	49.00	46.59	97.82	91.87	202.67
	e. Depreciation and Amortisation expense	33.94	36.78	34.41	70.72	68.27	143.08
	f. Other expenses	36.69	28.55	40.63	65.24	78.74	124.54
	Total Expenses	**1,000.73**	**1,344.81**	**1,230.45**	**2,345.53**	**2,395.65**	**4,456.77**
	Profit/ (Loss) before Exceptional item and tax (III-IV)	**27.13**	**15.83**	**6.57**	**42.96**	**10.66**	**69.14**
V	**Exceptional Items**	-					-
VI	**Profit/ (Loss) before tax (V-VI)**	27.13	15.83	6.57	42.96	10.66	69.14
VII	**Tax Expense:**	**7.89**	**4.07**	**2.23**	**11.96**	**3.58**	**35.52**
VIII	a. Current tax	7.83	5.34	2.63	13.17	5.46	20.29
0	b. Deferred tax charge/credit	0.06	-1.27	-0.40	-1.22	-1.87	15.23
IX	**Profit/ (Loss) for the period (VII-VIII)**	**19.24**	**11.77**	**4.34**	**31.00**	**7.07**	**33.62**
X	**Other Comprehensive Income**	-				-	-
	Items that will not be reclassified to profit or loss	-				-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	19.24	11.77	4.34	31.00	7.07	33.62
XI	**Paid up Capital**	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
	(Face value of the share- Rs. 10 each)						
	Other Equity	2,441.89	2,422.50	2,388.37	2,441.89	2,388.37	2,411.36
XII	**Earnings per share (of Rs. 10 each) (in Rupees)**						
XIII	a. Basic (in Rs)	0.19	0.12	0.04	0.31	0.07	0.34
	b. Diluted (in Rs)	0.19	0.12	0.04	0.31	0.07	0.34

Notes:

1	The finnacial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above Consolidated financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 13.11.2025
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The results are also available on the webiste of the Company www.concorddrugs.in

Place: Hyderabad
Date: 13.11.2025

Concord Drugs Limited ★ Hyderabad ★

S. Nath Reddy

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

STATEMENT OF Un -AUDITED STANDALONE FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30.09.2025

[Rs. in Lakhs]

Particulars		Quarterly ended			Half Year ended		Yearly
		30-Sep-25 (un Audited)	30-Jun-25 (un Audited)	30-Sep-24 (un Audited)	30-Sep-25 (un Audited)	30-Sep-24 (un Audited)	31-Mar-25 (Audited)
I	**Revenue from Operations**						
	a. Net sales from Operations	1,007.28	1,338.35	1,184.11	2,345.63	1,819.42	3,693.21
	b. Other Operating Income	0.24	-	0.96	0.24	0.96	1.44
II	**Other Income**						
III	**Total Revenue (I+II)**	**1,007.52**	**1,338.35**	**1,185.06**	**2,345.87**	**1,820.38**	**3,694.65**
IV	**Expenses**						
	a.Cost of Material Consumed	766.89	1,068.92	979.05	1,835.81	1,366.98	2,822.46
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-4.51	60.64	4.03	56.13	39.19	-58.05
	c. Employees Benefit Expenses	108.00	87.11	86.12	195.11	191.31	439.13
	d. Finance Costs	39.87	41.99	38.75	81.85	75.78	171.84
	e. Depreciation and Amortisation expense	33.70	36.55	34.09	70.24	67.63	141.80
	f. Other expenses	36.67	27.94	35.65	64.61	69.49	113.34
	Total Expenses	**980.61**	**1,323.15**	**1,177.69**	**2,303.75**	**1,810.37**	**3,630.52**
	Profit/ (Loss) before Exceptional item and tax (III-IV)	**26.91**	**15.20**	**7.37**	**42.11**	**10.01**	**64.13**
V	**Exceptional Items**	-	-	-	-	-	-
VI	**Profit/ (Loss) before tax (V-VI)**	26.91	15.20	7.37	42.11	10.01	64.13
VII	**Tax Expense:**	**7.52**	**4.06**	**1.96**	**11.58**	**3.42**	**34.56**
VIII	a. Current tax	7.80	5.15	2.90	12.95	5.29	18.99
0	b. Deferred tax charge/credit	-0.28	-1.09	-0.95	-1.37	-1.87	15.57
IX	**Profit/ (Loss) for the period (VII-VIII)**	**19.39**	**11.14**	**5.42**	**30.53**	**6.59**	**29.57**
X	**Other Comprehensive Income**	-	-	-	-	-	-
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	19.39	11.14	5.42	30.53	6.59	29.57
XI	**Paid up Capital**	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
	(Face value of the share- Rs. 10 each)						
	Other Equity	2,441.89	2,422.50	2,388.37	2,441.89	2,388.37	2,411.36
XII	**Earnings per share (of Rs. 10 each) (in Rupees)**						
XIII	a. Basic (in Rs)	0.19	0.11	0.05	0.31	0.07	0.30
	b. Diluted (in Rs)	0.19	0.11	0.05	0.31	0.07	0.30

Notes:

1	The finnacial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 13.11.2025
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The results are also available on the webiste of the Company www.concorddrugs.in

Place: Hyderabad
Date: 13.11.2025

Concord Drugs Limited ★ Hyderabad ★

S. Nath Ray

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement un Audited Consolidated Cash flow for the Six Months ended 30.09.2025 — **Amount in Lakhs**

Particulars	As on 30th September 2025		As at March 31, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		42.96		69.14
Adjustments for :				
Profit on sale of ASSets				
Depreciation and amortisation expense	70.72		143.08	
Finance costs	97.82		202.67	
Interest income	-0.24		-1.44	
Provision for Gratutiy				
		168.29		344.30
Operating profit before working capital changes		211.25		413.44
Changes in working capital: (Refer Note 40)				
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables	-363.60		-87.54	
Loans and Advances	-		-3.43	
Other Non Current assets	107.93		-219.52	
Inventories	-40.69		-234.57	
Other Current assets	-101.89		9.99	
Other bank balances	-9.16		-7.35	
Other Current financial Assets	-		-7.42	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	304.60		436.42	
Borrowings				
Other current financial liabilities	-0.00		112.66	
Other current liabilities	12.01		-37.45	
Current tax liabilities, net	11.37		-1.76	
Provisions	-		19.00	
Deferred tax on amalgamation				
Cash generated from operations		131.82		392.48
Net income tax paid		-13.17		-20.29
Net cash flow from operating activities (A)		118.64		372.19
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-6.09		-233.27	
Proceeds from maturiy of fixed deposits	-		-	
Investment				
- Subsidiaries	-		-	
- Others	0.24		1.44	
Net cash (used in) / flow from investing activities (B)		-5.85		-231.82
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-		-	
Finance costs	-97.82		-202.67	
Repayment of Borrowings	-33.74		67.89	
Repayment of short term Borrowings	23.56		-8.04	
Govt Grants				
Other equity Adjustment	-		-	
Net cash flow (used in) financing activities (C)		-107.99		-142.82
Net (decrease) in Cash and cash equivalents (A+B+C)		4.81		-2.45
Cash and cash equivalents at the beginning of the year		12.09		14.54
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		16.90		12.09
* Comprises:				
Balances with Banks				-
Others		16.90		12.09
		16.90		12.09

Concord Drugs Limited ★ Hyderabad ★

5, Nov

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement of un Audited Standalone Cash flow for the Six months ended 30.09.2025 — **Rs in Lakhs**

Particulars	As at 30th September, 2025		As at March 31, 2025	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		42.11		64.13
Adjustments for :				
Profit on sale of ASSets				
Depreciation and amortisation expense	70.24		141.80	
Finance costs	81.85		171.84	
Interest income	-0.24		-1.44	
Provision for Gratutiy				
		151.86		**312.20**
Operating profit before working capital changes		**193.97**		**376.33**
Changes in working capital: (Refer Note 40)				
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables	-363.94		129.89	
Loans and Advances	-		-3.43	
Other Non Current assets	107.93		-219.52	
Inventories	-48.10		-62.69	
Other Current assets	-105.65		31.49	
Other bank balances	-9.16		-7.35	
Other Current financial Assets	-		-7.42	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	302.70		3.92	
Borrowings				
Other current financial liabilities	-0.00		112.66	
Other current liabilities	10.93		-36.32	
Current tax liabilities, net	12.95		-1.25	
Provisions	-		19.00	
Deferred tax on amalgamation				
Cash generated from operations		**101.64**		**335.30**
Net income tax paid		-12.95		-18.99
Net cash flow from operating activities (A)		**88.68**		**316.31**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-6.09		-233.27	
Proceeds from maturiy of fixed deposits				
Investment				
- Subsidiaries	-		-	
- Others	0.24		1.44	
Net cash (used in) / flow from investing activities (B)		**-5.85**		**-231.82**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-		-	
Finance costs	-81.85		-171.84	
Repayment of Borrowings	-51.38		128.13	
Repayment of short term Borrowings	55.24		-42.95	
Govt Grants	-		-	
Other equity Adjustment	-		-	
Net cash flow (used in) financing activities (C)		-77.99		-86.66
Net (decrease) in Cash and cash equivalents (A+B+C)		4.84		-2.17
Cash and cash equivalents at the beginning of the year		11.54		13.71
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		16.38		11.54
* Comprises:				
Balances with Banks		-		0.00
Others		16.38		11.54
		16.38		**11.54**

Concord Drugs Limited ★ Hyderabad ★

S. N. T. M.

PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033
E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2025, and the year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2025 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.

2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India.


   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and

PUNDARIKASHYAM AND ASSOCIATES * HYDERABAD * Chartered Accountants

other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement,prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.



B. Surya Prakasa Rao

B.Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 25205125BMIBHL6214.

Place: Hyderabad
Date: 13-11-2025.

PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 30 September 2025, and the year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2025 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.

2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PUNDARIKASHYAM & ASSOCIATES HYDERABAD Chartered Accountants

4. The Statement includes the results of the following entities:
   Proton Remedies Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement,prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited financial results and other financial information, in respect of one subsidiary, whose unaudited financial results include total revenues of Rs 84.11 lakhs, total net profit after tax of Rs.0.47lakhs, for the half year ended Sep 30, 2025, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

B. Surya Prakasa Rao

B.Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 25205125BMIBHM3228.

Place: Hyderabad
Date: 13-11-2025.